- Home
- UHG vs FENC Comparison
UHG vs FENC Comparison
Compare UHG & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- FENC
- Stock Information
- Founded
- UHG 2004
- FENC 1996
- Country
- UHG United States
- FENC United States
- Employees
- UHG N/A
- FENC N/A
- Industry
- UHG Homebuilding
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UHG Consumer Discretionary
- FENC Health Care
- Exchange
- UHG Nasdaq
- FENC Nasdaq
- Market Cap
- UHG 242.0M
- FENC 225.4M
- IPO Year
- UHG N/A
- FENC 2001
- Fundamental
- Price
- UHG $4.18
- FENC $8.90
- Analyst Decision
- UHG
- FENC Strong Buy
- Analyst Count
- UHG 0
- FENC 2
- Target Price
- UHG N/A
- FENC $13.50
- AVG Volume (30 Days)
- UHG 123.7K
- FENC 64.2K
- Earning Date
- UHG 08-07-2025
- FENC 08-14-2025
- Dividend Yield
- UHG N/A
- FENC N/A
- EPS Growth
- UHG N/A
- FENC N/A
- EPS
- UHG 0.10
- FENC N/A
- Revenue
- UHG $445,963,017.00
- FENC $33,302,000.00
- Revenue This Year
- UHG N/A
- FENC $0.96
- Revenue Next Year
- UHG N/A
- FENC $51.71
- P/E Ratio
- UHG $43.65
- FENC N/A
- Revenue Growth
- UHG 7.51
- FENC N/A
- 52 Week Low
- UHG $1.60
- FENC $3.96
- 52 Week High
- UHG $6.93
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- UHG 52.56
- FENC 56.61
- Support Level
- UHG $4.08
- FENC $7.57
- Resistance Level
- UHG $4.38
- FENC $9.11
- Average True Range (ATR)
- UHG 0.30
- FENC 0.53
- MACD
- UHG -0.03
- FENC 0.06
- Stochastic Oscillator
- UHG 47.30
- FENC 75.56
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.